Discover investment opportunities in Cheap Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cheap Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cheap Stocks Under $1 using our Smart AI Filter.
8 stocks found for "Cheap Stocks Under $1"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.60 Risk measure | ±75.5% Price volatility | -1.2 Valuation | 0.00% Annual yield | |||
0.44 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
0.52 Risk measure | ±84.5% Price volatility | -2.2 Valuation | 0.00% Annual yield | |||
1.14 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
2.07 Risk measure | ±100.0% Price volatility | -4.2 Valuation | 0.00% Annual yield | |||
1.26 Risk measure | ±91.1% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
1.39 Risk measure | ±77.0% Price volatility | -0.5 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors contribute to the low stock price of TTOO?
A: T2 Biosystems (TTOO) faces challenges with commercialization of its diagnostic products and high cash burn rates, which can contribute to its stock price trading under $1. Investors should investigate the company's path to profitability and its competitive position in the healthcare diagnostics market.
Q: Are there growth prospects for NMTR in the biotech sector?
A: 9 Meters Biopharma (NMTR) operates in the biotech sector, focusing on treatments for rare and unmet medical needs. Growth depends on successful clinical trials and FDA approvals, which are inherently risky and can influence the stock's low market price.
Q: How does PSTV's focus on immunotherapy impact its stock valuation?
A: Plus Therapeutics (PSTV) is invested in oncology-focused immunotherapies. Its stock valuation is impacted by the high research costs and clinical success rates, common in biotech, creating potential volatility and contributing to its sub-$1 pricing.
Q: What competitive advantages might ADMP have in the pharmaceutical industry?
A: Adamis Pharmaceuticals (ADMP) competes in the generics and allergy relief spaces. Its focus on niche markets and FDA-approved products can provide some competitive advantages but also faces competition from larger firms, influencing its stock price.
Q: Does NAKD's involvement in e-commerce present investment opportunities?
A: Naked Brand Group (NAKD) transitioned to focus on the e-commerce sector after exiting apparel. Its success largely hinges on e-commerce growth strategies and consumer adoption trends, affecting the low stock valuation.
Q: How might TGIS's geographic focus influence its market performance?
A: TGIS's market performance may be affected by regional economic conditions and consumer demand within its geographic focus, impacting its competitive stance and thus, its stock pricing under $1.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe heavy selling pressure might have exhausted for i-80 Gold (IAUX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreThe FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read more